1 Metry DW, "Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature" 112 : 1430-1436, 2003
2 Quinn AM, "Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis" 141 : 683-687, 2005
3 Abood GJ, "Treatment strategies in toxic epidermal necrolysis syndrome: where are we at" 29 : 269-276, 2008
4 Brambilla G, "Treatment of toxic epidermal necrolysis (TEN)" 15 : 17-21, 2002
5 Abe R, "Toxic epidermal necrolysis and Stevens- Johnson syndrome are induced by soluble Fas ligand" 162 : 1515-1520, 2003
6 Garcia-Doval I, "Toxic epidermal necrolysis and Stevens- Johnson syndrome" 136 : 323-327, 2000
7 Wolkenstein P, "Toxic epidermal necrolysis" 18 : 485-495, 2000
8 Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs" 128 : 35-44, 2008
9 Ducic I, "Outcome of patients with toxic epidermal necrolysis syndrome revisited" 110 : 768-773, 2002
10 Niebanck AE, "Neutropenia following IVIG therapy in pediatric patients with immune mediated thrombocytopenia" 27 : 145-147, 2005
1 Metry DW, "Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature" 112 : 1430-1436, 2003
2 Quinn AM, "Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis" 141 : 683-687, 2005
3 Abood GJ, "Treatment strategies in toxic epidermal necrolysis syndrome: where are we at" 29 : 269-276, 2008
4 Brambilla G, "Treatment of toxic epidermal necrolysis (TEN)" 15 : 17-21, 2002
5 Abe R, "Toxic epidermal necrolysis and Stevens- Johnson syndrome are induced by soluble Fas ligand" 162 : 1515-1520, 2003
6 Garcia-Doval I, "Toxic epidermal necrolysis and Stevens- Johnson syndrome" 136 : 323-327, 2000
7 Wolkenstein P, "Toxic epidermal necrolysis" 18 : 485-495, 2000
8 Mockenhaupt M, "Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs" 128 : 35-44, 2008
9 Ducic I, "Outcome of patients with toxic epidermal necrolysis syndrome revisited" 110 : 768-773, 2002
10 Niebanck AE, "Neutropenia following IVIG therapy in pediatric patients with immune mediated thrombocytopenia" 27 : 145-147, 2005
11 Mukasa Y, "Management of toxic epidermal necrolysis and related syndromes" 84 : 60-65, 2008
12 Wolf R, "Life-threatening acute adverse cutaneous drug reactions" 23 : 171-181, 2005
13 Cuerda Galindo E, "Fixed drug eruption from piroxicam" 18 : 586-587, 2004
14 Castana O, "Diseases mimicking a burn-outcome and treatment" 18 : 130-132, 2005
15 Bachot N, "Differential diagnosis of severe cutaneous drug eruptions" 4 : 561-572, 2003
16 Halevy S, "Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel" 58 : 25-32, 2008
17 Lonjou C, "A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs" 18 : 99-107, 2008